NRBO Share Price | NeuroBo Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does NeuroBo Pharmaceuticals, Inc. do?

Overview:NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pharmaceuticals to treat neurodegenerative disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 13.56 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -2.54 Return on Equity: -570.84% Price to Book: 3.09Contact Details:Address: 200 BERKELEY ST., FL 19, BOSTON MA: 02116 Tel: ['1 857 7029600', '1 917 6336086'] Fax: 1 734 2930444 Website: https://www.neurobopharma.com/

Q: Is NeuroBo Pharmaceuticals, Inc. technically bullish or bearish?

As of 6 August 2025, the technical trend for NeuroBo Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish outlook, while the weekly MACD and KST suggest a mildly bullish sentiment. The monthly RSI is bullish, but the Bollinger Bands show a mixed signal with a bullish weekly and mildly bearish monthly trend. In terms of performance, the stock has seen a significant decline over the longer term, with a 1Y return of -73.02% compared to the S&P 500's 17.14%, and a staggering -99.94% over 5Y against the S&P 500's 96.61%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

362.26 k

Shareholding (Sep 2025)

FII

0.08%

Held by 3 FIIs

DII

99.11%

Held by 1 DIIs

Promoter

0.00%

How big is NeuroBo Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, NeuroBo Pharmaceuticals, Inc. has a market capitalization of 13.56 million and reported net sales of 0.00 million with a net profit of -24.54 million over the last four quarters. Shareholder's funds are 7.93 million, and total assets amount to 16.26 million.

View full answer

What does NeuroBo Pharmaceuticals, Inc. do?

22-Jun-2025

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative disorders, with a market cap of $13.56 million and a recent net profit of -$4 million. The company is classified as a micro-cap and has no dividend yield.

View full answer

Who are in the management team of NeuroBo Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of NeuroBo Pharmaceuticals, Inc. includes Chairman Douglas Swirsky, CEO Dr. Jeong Gu Kang, and COO Akash Bakshi, along with independent directors Jason Groves, Jeong Gyun Oh, and Michael Salsbury.

View full answer

Is NeuroBo Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 6, 2025, NeuroBo Pharmaceuticals, Inc. shows a mildly bearish trend with mixed signals from technical indicators, having declined 73.02% over the past year and 99.94% over five years compared to the S&P 500's gains.

View full answer

Compare NeuroBo Pharmaceuticals, Inc. with Similar Stocks

22nd Century Group, Inc.Catalyst Biosciences, Inc.Vascular Biogenics Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-2.24

Return on Equity

-262.41%

Price to Book

0.81

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-84.78%

6 Months

-87.11%

1 Year

-91.44%

2 Years

-97.02%

3 Years

-97.52%

4 Years

-99.94%

5 Years

-99.99%

NeuroBo Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-209.69%

EBIT to Interest (avg)

-16.24

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.54

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

4.38%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.81

EV to EBIT

0.53

EV to EBITDA

0.53

EV to Capital Employed

1.15

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

219.23%

ROE (Latest)

-262.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.82%)

Foreign Institutions

Held by 3 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 40.35% vs -50.00% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.50",
          "val2": "-6.30",
          "chgp": "44.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.30",
          "chgp": "-133.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.40",
          "val2": "-5.70",
          "chgp": "40.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -120.80% vs 10.71% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.80",
          "val2": "-15.90",
          "chgp": "-81.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "3.00",
          "chgp": "-90.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.60",
          "val2": "-12.50",
          "chgp": "-120.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.50

-6.30

44.44%

Interest

0.00

Exceptional Items

-0.10

0.30

-133.33%

Consolidate Net Profit

-3.40

-5.70

40.35%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 40.35% vs -50.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-28.80

-15.90

-81.13%

Interest

0.00

Exceptional Items

0.30

3.00

-90.00%

Consolidate Net Profit

-27.60

-12.50

-120.80%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -120.80% vs 10.71% in Dec 2023

All Annual Results

Company CV

About NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). It also focused on developing capsule formulation of niclosamide for coronavirus indications.

Company Coordinates

Company Details

200 BERKELEY ST., FL 19 , BOSTON MA : 02116

Tel: 1 857 70296001 917 6336086

https://www.neurobopharma.com/

Registrar Details